Ashling Wahner

Moh’d Khushman, MD, discusses INCA33890’s mechanism of action, phase 1 safety and efficacy data, and the design of NEXERA-303 in MSS colorectal cancer.

With multiple ADCs now available for use in gynecologic cancers, treatment decision-making incorporates biomarker nuances and raises sequencing questions.

The FDA approved nogapendekin alfa inbakicept plus BCG for BCG-unresponsive NMIBC with high-grade papillary-only tumors.

Novel NAMPT inhibitors may circumvent the limited tolerability of previously studied agents and improve treatment outcomes in AML and MDS.

Lung cancer experts discuss emerging strategies after immunotherapy in advanced squamous NSCLC, including updated PRESERVE-003 data from WCLC 2026.

The FDA has approved pirtobrutinib for the treatment of adult patients with previously untreated CLL or SLL harboring no known 17p deletion.

Experts spotlight the variety of breast cancer research being presented at the 2026 ESMO Congress.

Jason Hafron, MD, discusses the emotional, clinical, and financial burden of false positive cancer screening results and improved risk stratification.

The FDA has approved belzutifan (Welireg) plus lenvatinib (Lenvima) for use in patients with advanced renal cell carcinoma with a clear cell component after PD-1 or PD-L1 inhibition.

Brandon Huffman, MD, discusses INCB161734’s mechanism of action, phase 1 data, and the DAWN-303 trial design in KRAS G12D–mutated pancreatic cancer.

The FDA has approved lutetium Lu 177 dotatate injection for SSTR-positive GEP-NETs, including foregut, midgut, and hindgut NETs.

The FDA approved sevabertinib for advanced or metastatic nonsquamous NSCLC harboring HER2 (ERBB2) TKD activating mutations.

The FDA approved camizestrant plus a CDK4/6 inhibitor for hormone receptor–positive, HER2-negative metastatic breast cancer that acquires an ESR1 mutation.

Brain cancer experts explain the current wave of surgical advances and advocate for team-based, multidisciplinary strategies to individualize patient care.

The MAPKeeper-301 trial is evaluating frontline atebimetinib plus chemotherapy vs standard chemotherapy in metastatic pancreatic ductal adenocarcinoma.

The ASPEN-09-03 trial is evaluating evorpacept plus trastuzumab and chemotherapy in previously treated HER2-positive metastatic breast cancer.

Charles E. Geyer, MD, discusses data from the DESTINY-Breast05 safety analysis evaluating ILD and radiation pneumonitis outcomes in HER2+ breast cancer.

The phase 3 DAWN-303 trial is evaluating the oral KRAS G12D inhibitor INCB161734 in previously untreated, KRAS G12D–mutated metastatic PDAC.

Sara Nunnery, MD, MSCI, and Irene M. Kang, MD, discuss toxicity and monitoring considerations for the use of ADCs in metastatic TNBC.

Komal Jhaveri, MD, FACP, discusses the design of the SERENA-6 trial and larger questions for the breast cancer field that remain after seeing its results.

Sara Nunnery, MD, MSCI, and Kelly E. McCann, MD, PhD, discuss practice-changing data with T-DXd for HER2-positive breast cancer.

Komal Jhaveri, MD, FACP, discusses the role of CDK4/6 inhibitors for patients with hormone receptor–positive disease and how oral SERD use is changing.

Antibodies directed against TNFR2, a regulator in the tumor microenvironment that promotes tumor cell proliferation, have shown promise in T-cell lymphoma and ovarian cancer.

The FDA has issued a CRL to the NDA seeking the approval of the investigational agent 177Lu-edotreotide for the treatment of patients with GEP-NETs.

Breast cancer experts share insights on how recently approved indications for 3 ADCs will affect clinical practice.

Paolo Tarantino, MD, PhD, discusses key data with ADCs in breast cancer that were presented at ASCO 2026.

The FDA has approved lutetium Lu 177 vipivotide tetraxetan plus an ARPI for PSMA-positive metastatic hormone-sensitive prostate cancer.

Andrew H. Ko, MD, discusses how TTFields works and data that supported the FDA approval of Optune Pax for patients with pancreatic cancer.

Sarcoma management demands coordinated, subtype-specific care and treatment sensitivities delivered by a dedicated multidisciplinary team.

Two decades of biomarker-driven progress have reshaped lung cancer management, but late diagnosis, unequal treatment access, and underfunding remain